Advancing Therapeutic Strategies for Nonsense-Related Diseases: From Small Molecules to Nucleic Acid-Based...

Area of Science:

• Genetics
• Molecular Biology
• Pharmacology

Background:

• Nonsense mutations lead to premature termination codons (PTCs) in mRNA, producing nonfunctional proteins.
• These mutations are responsible for severe genetic nonsense-related diseases (NRDs) like cystic fibrosis and Duchenne muscular dystrophy.
• Current treatments for NRDs are limited, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To review promising therapeutic approaches for genetic nonsense-related diseases.
• To discuss emerging strategies for nonsense suppression in precision medicine.

Main Methods:

• Review of small molecule therapies, including translational readthrough-inducing drugs (TRIDs) and nonsense-mediated decay (NMD) inhibitors.
• Exploration of nucleic acid-based therapies such as gene editing, anticodon engineered-tRNA (ACE-tRNA), and mRNA therapy.

Main Results:

• Various therapeutic strategies show promise for treating NRDs by targeting the molecular mechanisms of nonsense mutations.
• Small molecules and nucleic acid-based therapies offer potential avenues for restoring protein function.

Conclusions:

• Developing effective nonsense suppression therapies is critical for precision medicine in treating NRDs.
• Future research should focus on refining existing approaches and exploring personalized, integrated treatments for improved patient outcomes.